

**Supplemental Table 1. Baseline characteristics by baseline glycemic subgroup**

	<b>No Diabetes N=2,605</b>	<b>Pre-diabetes N=1,748</b>	<b>Normoglycemic N=857</b>	<b>p-value</b>
<b>Age – yr</b>	66.2±11.6	67.1±11.1	64.5±12.5	<0.001
<b>Sex - no (%)</b>				0.44
Female	632 (24.3)	432 (24.7)	200 (23.3)	
Male	1,973 (75.7)	1,316 (75.3)	657 (76.7)	
<b>Race – no. (%)†</b>				0.77
White	1,844 (70.8)	1,242 (71.1)	602 (70.2)	
Asian	625 (24.0)	419 (24.0)	206 (24.0)	
Black or African American	98 ( 3.8)	61 ( 3.5)	37 ( 4.3)	
Other	38 ( 1.5)	26 ( 1.5)	12 ( 1.4)	
<b>Region – no. (%)</b>				0.063
Asia/Pacific	617 (23.7)	413 (23.6)	204 (23.8)	
Europe	1,203 (46.2)	833 (47.7)	370 (43.2)	
North America	342 (13.1)	226 (12.9)	116 (13.5)	
South America	443 (17.0)	276 (15.8)	167 (19.5)	
<b>Body-mass index§</b>	27.2±5.7	27.4±5.8	26.8±5.6	0.023
<b>HbA1c – %</b>	5.8±0.4	6.0±0.3	5.3±0.2	<0.001
<b>Estimated GFR</b>				
Mean – ml/min/1.73m <sup>2</sup>	67.8±19.2	67.1±18.8	69.2±20.0	0.010
Rate of < 60 ml/min/1.73m <sup>2</sup> – no. (%)	944 (36.3)	643 (36.8)	301 (35.2)	0.43
<b>Systolic Blood Pressure – mmHg</b>	120.6±16.1	120.5±15.8	120.7±16.7	0.84
<b>NYHA functional classification – no. (%)</b>				0.048
II	1,841 (70.7)	1,232 (70.5)	609 (71.1)	
III	743 (28.5)	507 (29.0)	236 (27.5)	
IV	21 (0.8)	9 (0.5)	12 (1.4)	
<b>Left ventricular ejection fraction – %</b>	30.9±6.9	30.9±6.9	31.0±6.8	0.83
<b>Median NT-proBNP (IQR) – pg/ml</b>	1412.8 (828.0-2492.5)	1438.7 (832.1-2615.8)	1360.2 (819.0-2341.6)	0.094
<b>Median KCCQ-TSS (IQR)</b>	79.2 (61.5-91.7)	79.2 (60.4-91.7)	79.2 (62.5-93.8)	0.11
<b>Principal cause of heart failure – no. (%)</b>				0.013
Ischemic	1,341 (51.5)	935 (53.5)	406 (47.4)	
Non-ischemic	1,033 (39.7)	666 (38.1)	367 (42.8)	
Unknown	231 (8.9)	147 (8.4)	84 (9.8)	
<b>Medical history – no. (%)</b>				
Prior hospitalization for heart failure	1,202 (46.1)	789 (45.1)	413 (48.2)	0.14
Atrial fibrillation	1,022 (39.2)	700 (40.0)	322 (37.6)	0.22
<b>Heart failure medication– no (%)</b>				
Diuretic	2,124 (81.5)	1,453 (83.1)	671 (78.3)	0.003
ACE-inhibitor	1,489 (57.2)	1,012 (57.9)	477 (55.7)	0.28
ARB	692 (26.6)	463 (26.5)	229 (26.7)	0.90
Sacubitril-valsartan	279 (10.7)	178 (10.2)	101 (11.8)	0.21
Beta-blocker	2,491 (95.6)	1,674 (95.8)	817 (95.3)	0.61
Mineralocorticoid receptor antagonist	1,841 (70.7)	1,233 (70.5)	608 (70.9)	0.83
Digitalis	458 (17.6)	304 (17.4)	154 (18.0)	0.72
Statin	1,607 (61.7)	1,143 (65.4)	464 (54.1)	<0.001

P values presented are for the comparison between prediabetes and normoglycemia.

Data presented as mean (SD) unless otherwise indicated.

Percentages may not total 100 because of rounding.

ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, GFR glomerular filtration rate, IQR interquartile range, LVEF left ventricular ejection fraction, MRA mineralocorticoid receptor antagonist, N-terminal pro-B-type natriuretic peptide and NYHA New York Heart Association. KCCQ-TSS Kansas City Cardiomyopathy Questionnaire total symptom score - range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations associated with heart failure. A score of 75 or above is considered to reflect satisfactory health status.

† Race was reported by the investigators

§ The body-mass index is the weight in kilograms divided by the square of the height in meters.

## Supplemental Figure 1. Effect of dapagliflozin on incident diabetes by relevant subgroups

No heterogeneity of the treatment effect on incident T2D was found except for nominal interactions for age and baseline NT-proBNP.

